Considering quantity and quality of life in metastatic castration-naive prostate cancer
Mené dans 34 pays sur 1 199 patients atteints d'un cancer métastatique de la prostate à haut risque récemment diagnostiqué, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale et de la survie sans progression, et les effets sur les symptômes auto-déclarés par les patients et la qualité de vie, de l'ajout d'un traitement combinant abiratérone acétate et prednisone à une thérapie anti-androgénique (durée médiane de suivi : 30,9 mois)
The treatment approach for metastatic prostate cancer is rapidly evolving. Drugs that were previously used primarily in the setting of castration-resistant prostate cancer have now been shown to improve survival in castration-naive disease. Specifically, both abiraterone acetate (in combination with prednisone)1,2 and docetaxel3 have been shown to confer an overall survival advantage when used with androgen deprivation therapy (ADT) in patients with metastatic castration-naive prostate cancer. Although these are promising developments, it is important that these treatments improve both quantity and quality of life in patients.
The Lancet Oncology , commentaire, 2017